

ONE HUNDRED THIRTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-2927  
Minority (202) 225-3641

August 13, 2013

Dr. Carmen A. Catizone, RPh, DPh  
Executive Director  
National Association of Boards of Pharmacy  
1600 Feehanville Drive  
Mount Prospect, IL 60056

Dear Dr. Catizone:


Thank you for appearing before the Subcommittee on Health on Tuesday, July 16, 2013, to testify at the hearing entitled "Reforming the Drug Compounding Regulatory Framework."

During the hearing, Members asked you to provide additional information for the record, and those requests are attached. The format of your responses to these requests should be as follows: (1) the name of the Member whose request you are addressing, (2) the complete text of the request you are addressing in bold, and (3) your response to that request in plain text.

To facilitate the printing of the hearing record, please respond to these questions and requests by the close of business on Tuesday, August 27, 2013. Your responses should be mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [Sydne.Harwick@mail.house.gov](mailto:Sydne.Harwick@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

  
Joseph R. Pitts  
Chairman  
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

## **Attachment —Member Requests for the Record**

*During the hearing, Members asked you to provide additional information for the record and you indicated that you would provide that information. For your convenience, descriptions of the requested information are provided below.*

### **The Honorable John D. Dingell**

1. Do you believe that it is important to have clear lines of division between FDA and State boards of pharmacy when it comes to regulating compounding pharmacies? Please elaborate.
2. Does Section 503(a), as currently drafted and interpreted, recognize the existence of these compounding outsourcers and our reliance on them? Please elaborate.